Show overview
Breast Cancer Update has been publishing since 2023, and across the 3 years since has built a catalogue of 113 episodes. That works out to roughly 120 hours of audio in total. Releases follow a fortnightly cadence, with the show now in its 25th season.
Episodes typically run thirty-five to sixty minutes — most land between 46 min and 1h 16m — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.
The show is actively publishing — the most recent episode landed 5 days ago, with 26 episodes already out so far this year. The busiest year was 2025, with 48 episodes published. Published by Dr. Neil Love.
From the publisher
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
Latest Episodes
View all 113 episodesFor Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress
For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress
For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway
HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know
HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy
Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan
S25 Ep 55Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway
Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.CME information and select publications here.